Melanotan II
Melanotan II is a synthetic cyclic melanocortin peptide distinct from both afamelanotide implants and prescription bremelanotide products.
The short version
- Why people discuss it
- Discussed for tanning/pigmentation and libido; those interests do not establish UV protection. Community interest does not establish benefit or a suitable treatment.
- What it is
- Melanotan II is a synthetic cyclic melanocortin peptide distinct from both afamelanotide implants and prescription bremelanotide products.
- Biggest caution
- Pigmentation or sexual-response reports do not establish safe tanning or sexual-health use. Product identity, dosing, cardiovascular effects, pigment changes and long-term safety require clinical evaluation.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 0.25–0.5 mg
- Frequency
- Once daily during loading
- Duration / phase
- 7–14 days; maintenance varies
Community pattern for an unapproved product Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
0.25→1 mg SC daily over 4–8 weeks; maintenance 0.5–1 mg 1–2 times/week.
- Peptidepedia — saved source reviewed September 27, 2026
0.1 mg start, then 0.25 mg daily for 2–4 weeks; maintenance 0.5–1 mg 1–2 times/week.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27
- Peptidepedia — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27